ProCE Banner Activity

REACH: Long-term Analysis of Dose-Optimized Hydroxyurea for Treatment of Pediatric Patients With Sickle Cell Anemia in Sub-Saharan Africa

Conference Coverage

In this long-term analysis of the ongoing phase I/II REACH trial, hydroxyurea treatment with an average duration of 85 months was tolerable and effective in children with sickle cell anemia living in Sub-Saharan Africa.

Released: December 12, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.